Abstract:The gp41 transmembrane domain of the envelope glycoprotein of the human immunodeficiency virus (HIV) modulates the conformation of the viral envelope spike. During the HIV fusion process, C-terminal heptad repeat (CHR, C34) wrap antiparallel to the N-terminal heptad repeat (NHR, N36) helices to form a stable six-helix bundle (6-HB) core structure, which brings the viral and cell membranes into close proximity for fusion. Therefore, inhibiting the formation of 6-HB is considered to be a key activity of an effective HIV-1 fusion inhibitor. The level of arachidonic acid (AA) is increased in HIV infected patients. Our study provides a new insight into the functional role of AA during the formation of HIV-1 gp41 6-HB. Native polyacrylamide gel electrophoresis (N-PAGE), enzyme-linked-immunosorbent serologic assay (ELISA) and circular dichroism (CD) spectroscopy were used to investigate the inhibition of AA for the formation of 6-HB. Molecular docking technique was adopted to explore the underlying mechanism. HIV-1 JR-FL (R5 strain) Envelope was adopted to determine the inhibition effect of AA. AA is shown to interfere with the formation of α-helical complexes of N36 and C34 by N-PAGE, ELISA and CD spectroscopy. The isotherm titration microcalorimetry (ITC) results indicate there is a single class of binding site on N36. ΔH and ΔS are -12.43 kJ mol-1 and 70.07 J mol-1 K-1, respectively, indicating hydrophobic interaction and electrostatic forces are the main acting forces. The molecular docking results manifest that AA interacts with the hydrophobic residues (Trp-571, Leu-568, Val-570 and Leu-576) and ionic interactions occur between Arg-579 and the -COOH of AA. The inhibitory activity of AA on HIV-1 JR-FL is quantified by 50% effective concentration (EC50) and 90% effective concentration (EC90), which are 31.42 ± 1.08 and 133.47 ± 18.10 μg mL-1, respectively. All the results indicate that AA is able to inhibit the formation of 6-HB but cannot disrupt the preformed 6-HB. Therefore, AA is a potential inhibitor for the viral fusion/entry.

Acid Native Polyacrylamide Gel Electrophoresis:A Method for Studying the Mechanism of Action of HIV Entry Inhibitor ADS-J1

ADS-J 1 Inhibits Human Immunodeficiency Virus Type 1 Entry by Interacting with the Gp 41 Pocket Region and Blocking Fusion-Active Gp 41 Core Formation

ADS-J1 Inhibits HIV-1 Infection and Membrane Fusion by Targeting the Highly Conserved Pocket in the Gp41 NHR-trimer.

ADS-J1, an Entry Inhibitor Targeting Gp41, Prevents HIV-1 Transmission in the in Vitro and Ex Vivo Models.

ADS-J21 is a Novel HIV-1 Entry Inhibitor Targeting Gp41

The Anti-Hiv-1 Entrance Activity and Mechanism of Action of Myriceric Acid B from Rhoiptelea Chiliantha Diels Et Hand-Mazz

Investigation of the inhibition effect of arachidonic acid on the core structure of the HIV-1 gp41

N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein

A Screening Assay for Antiviral Compounds Targeted to the HIV-1 Gp41 Core Structure Using a Conformation-Specific Monoclonal Antibody

Study of the Cyclic Peptide Binding to HIV-1 Gp41 NHR

Structure-Based Identification of Small Molecule Antiviral Compounds Targeted to the Gp41 Core Structure of the Human Immunodeficiency Virus Type 1

Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte.

[Virtual Screening of Small Molecular HIV-1 Entry Inhibitor NC-2 Targeting Gp120 and Its Action Mechanism].

ADS-J1 Inhibits Semen-Derived Amyloid Fibril Formation and Blocks Fibril-Mediated Enhancement of HIV-1 Infection.

High Throughput Screening and Characterization of HIV-1 Entry Inhibitors Targeting Gp41: Theories and Techniques.

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

An Amphipathic Peptide Targeting the Gp41 Cytoplasmic Tail Kills HIV-1 Virions and Infected Cells

The Mechanism by Which Molecules Containing the HIV Gp41 Core-Binding Motif HXXNPF Inhibit HIV-1 Envelope Glycoprotein-Mediated Syncytium Formation.

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds